What were the treatment arms, and their duration, for the UNITI-1 and UNITI-2 induction studies?

A. Ustekinumab ~6 mg/kg or 130 mg, versus adalimumab over a 12-week period

B. Ustekinumab ~3 mg/kg or 220 mg versus vedolizumab over an 8-week period

C. Ustekinumab ~6 mg/kg or 130 mg, versus placebo over an 8-week period

D. Ustekinumab ~4 mg/kg versus adalimumab and placebo over a 12-week period